Altimmune (ALT) Competitors $5.77 +0.18 (+3.22%) Closing price 05/22/2025 04:00 PM EasternExtended Trading$5.80 +0.03 (+0.43%) As of 05/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALT vs. BEAM, APGE, SDGR, CNTA, BHC, ARQT, AGIO, GLPG, IRON, and IDYAShould you be buying Altimmune stock or one of its competitors? The main competitors of Altimmune include Beam Therapeutics (BEAM), Apogee Therapeutics (APGE), Schrödinger (SDGR), Centessa Pharmaceuticals (CNTA), Bausch Health Companies (BHC), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), Disc Medicine (IRON), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Altimmune vs. Beam Therapeutics Apogee Therapeutics Schrödinger Centessa Pharmaceuticals Bausch Health Companies Arcutis Biotherapeutics Agios Pharmaceuticals Galapagos Disc Medicine IDEAYA Biosciences Altimmune (NASDAQ:ALT) and Beam Therapeutics (NASDAQ:BEAM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, earnings, valuation, profitability, dividends, media sentiment and institutional ownership. Is ALT or BEAM more profitable? Beam Therapeutics has a net margin of -41.07% compared to Altimmune's net margin of -199,076.92%. Beam Therapeutics' return on equity of -16.22% beat Altimmune's return on equity.Company Net Margins Return on Equity Return on Assets Altimmune-199,076.92% -55.81% -50.60% Beam Therapeutics -41.07%-16.22%-10.94% Does the media prefer ALT or BEAM? In the previous week, Altimmune had 13 more articles in the media than Beam Therapeutics. MarketBeat recorded 20 mentions for Altimmune and 7 mentions for Beam Therapeutics. Beam Therapeutics' average media sentiment score of 1.74 beat Altimmune's score of 0.94 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Altimmune 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Does the MarketBeat Community believe in ALT or BEAM? Beam Therapeutics received 6 more outperform votes than Altimmune when rated by MarketBeat users. However, 72.09% of users gave Altimmune an outperform vote while only 59.13% of users gave Beam Therapeutics an outperform vote. CompanyUnderperformOutperformAltimmuneOutperform Votes6272.09% Underperform Votes2427.91% Beam TherapeuticsOutperform Votes6859.13% Underperform Votes4740.87% Do insiders & institutionals believe in ALT or BEAM? 78.1% of Altimmune shares are owned by institutional investors. Comparatively, 99.7% of Beam Therapeutics shares are owned by institutional investors. 4.1% of Altimmune shares are owned by insiders. Comparatively, 4.2% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, ALT or BEAM? Altimmune has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Do analysts recommend ALT or BEAM? Altimmune presently has a consensus price target of $20.20, indicating a potential upside of 250.09%. Beam Therapeutics has a consensus price target of $48.75, indicating a potential upside of 182.77%. Given Altimmune's higher possible upside, equities research analysts plainly believe Altimmune is more favorable than Beam Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Altimmune 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Beam Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has better earnings and valuation, ALT or BEAM? Altimmune has higher earnings, but lower revenue than Beam Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAltimmune$20K23,399.37-$88.45M-$1.26-4.58Beam Therapeutics$63.58M27.27-$132.53M-$4.61-3.74 SummaryBeam Therapeutics beats Altimmune on 11 of the 18 factors compared between the two stocks. Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALT vs. The Competition Export to ExcelMetricAltimmunePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$467.99M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-3.729.0626.7119.71Price / Sales23,399.37251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book2.106.456.774.50Net Income-$88.45M$143.98M$3.23B$248.22M7 Day Performance-0.17%2.41%1.80%0.56%1 Month Performance18.97%4.56%11.10%13.17%1 Year Performance-26.87%-2.67%17.11%7.30% Altimmune Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALTAltimmune2.6245 of 5 stars$5.77+3.2%$20.20+250.1%-26.9%$467.99M$20,000.00-3.7250News CoverageAnalyst UpgradeAnalyst RevisionGap UpBEAMBeam Therapeutics3.1638 of 5 stars$18.24+4.8%$48.75+167.3%-30.7%$1.83B$63.58M-10.36510Positive NewsAPGEApogee Therapeutics2.1488 of 5 stars$39.58+6.1%$94.60+139.0%-15.7%$1.78BN/A-16.3691Positive NewsSDGRSchrödinger2.9324 of 5 stars$24.17+1.1%$32.80+35.7%-6.3%$1.77B$207.54M-10.33790News CoverageCNTACentessa Pharmaceuticals3.5384 of 5 stars$13.15+6.9%$27.00+105.3%+44.2%$1.75B$6.85M-8.59200Positive NewsAnalyst UpgradeInsider TradeAnalyst RevisionGap UpBHCBausch Health Companies4.1617 of 5 stars$4.79+4.2%$7.42+55.0%-29.4%$1.73B$9.73B-39.8719,900Gap UpARQTArcutis Biotherapeutics2.7526 of 5 stars$14.39+6.4%$18.80+30.6%+37.7%$1.72B$212.82M-8.04150News CoverageInsider TradeAGIOAgios Pharmaceuticals3.9759 of 5 stars$29.14+6.7%$56.00+92.2%-11.5%$1.69B$37.04M2.57390Positive NewsGLPGGalapagos0.4827 of 5 stars$25.07-1.0%$25.33+1.1%+2.1%$1.65B$288.19M0.001,310Positive NewsIRONDisc Medicine3.1625 of 5 stars$46.61+5.4%$98.80+112.0%+44.8%$1.61BN/A-11.7130Positive NewsInsider TradeIDYAIDEAYA Biosciences3.6725 of 5 stars$18.35+5.3%$53.58+192.0%-54.9%$1.61B$7M-5.5680Analyst Forecast Related Companies and Tools Related Companies Beam Therapeutics Alternatives Apogee Therapeutics Alternatives Schrödinger Alternatives Centessa Pharmaceuticals Alternatives Bausch Health Companies Alternatives Arcutis Biotherapeutics Alternatives Agios Pharmaceuticals Alternatives Galapagos Alternatives Disc Medicine Alternatives IDEAYA Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALT) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
